Hannah Betts, the Daily Mail’s beauty editor, has rounded up five gel polishes she says are free of trimethylbenzoyl diphenylphosphine oxide (TPO) and marketed as non-toxic, amid growing regulatory scrutiny of nail‑product ingredients. The piece, published on the Daily Mail’s lifestyle pages, frames the recommendations as part of a wider consumer shift toward safer, cleaner beauty options.
Betts noted that European regulators have banned TPO — an ingredient used in some gel polishes — over concerns about potential toxicity, though the chemical is still available for sale in the U.K. Her article pairs product picks with commentary from an independent NHS dermatologist who asked to remain anonymous, and a roundup of other current skincare and makeup launches aimed at midlife shoppers.
In the story Betts warns that many recent anti‑ageing product launches are accompanied by “big” claims and short testing windows, and she describes consulting the unnamed NHS skin specialist to help separate evidence‑backed ingredients from marketing. The dermatologist told Betts that ingredients with proven results include retinol, vitamin C, azelaic acid and niacinamide, and she stressed that markedly effective treatments often require prescription access. The dermatologist recommended using azelaic acid together with sunscreen for hyperpigmentation and expressed approval for certain over‑the‑counter regimens such as Neoretin and Heliocare’s pigment solutions.
Betts’s article also references recent product launches that have drawn consumer attention. She cites Skin Rocks’s Hyperpigmentation Serum, which combines niacinamide and vitamin C and has generated strong early reviews, and Beauty Pie’s Youthbomb Extreme Retinal Triple Renewal Serum as an example of a potent non‑prescription retinal formulation. Betts wrote that some products — including long‑standing cult favourites such as Crème de La Mer — can produce visible improvements for individual users even if clinicians remain sceptical of some marketing language.
The Daily Mail piece includes the standard disclosure that its journalists curate products and that purchases made via links on the page may earn commission. Betts emphasised that, when choosing nail and skin products, consumers should look for formulations that avoid disputed ingredients such as TPO and pay attention to established active ingredients supported by dermatological evidence.
Regulatory context is central to the article’s framing. The European Union moved to restrict TPO after assessments raised concerns about its safety, particularly in products that may come into prolonged contact with skin. Manufacturers and retailers in jurisdictions outside the EU, including the U.K., still sell some products containing the chemical, prompting consumer guidance from editors and clinicians about how to select alternatives.
Betts also used the column to highlight other beauty launches ranging from a heat‑activated Amika anti‑frizz hair treatment to Violette_France’s Plume Lip texture product and more affordable lip balms such as NYX’s Smushy Matte Lip Balm. Across the recommendations she reiterated the dermatologist’s caution that product efficacy timelines vary and that many high‑cost launches have limited independent testing. The article concludes by advising readers to prioritise ingredients with clinical support and to be wary of short trial periods used in marketing that may not capture longer‑term results.